+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Overactive Bladder Treatment Market Research Report by Therapy Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4968613
  • Report
  • July 2021
  • Region: Global
  • 192 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Overactive Bladder Treatment Market will Grow to USD 5,069.22 Million by 2026, at a CAGR of 3.55%

FEATURED COMPANIES

  • Allergan plc
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Endo International plc.
  • Intas Biopharmaceuticals
  • Johnson & Johnson
  • MORE
The Global Overactive Bladder Treatment Market size was estimated at USD 4,111.02 Million in 2020 and expected to reach USD 4,243.20 Million in 2021, at a Compound Annual Growth Rate (CAGR) 3.55% to reach USD 5,069.22 Million by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Overactive Bladder Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Therapy Type, the Overactive Bladder Treatment Market was examined across Anticholinergic, BOTO, Darifenacin, Fesoterodine, Mirabegron, Neurostimulation, Oxybutynin, and Solifenacin.
  • Based on Disease Type, the Overactive Bladder Treatment Market was examined across Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity.
  • Based on Geography, the Overactive Bladder Treatment Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Overactive Bladder Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Overactive Bladder Treatment Market, including Allergan plc, Apotex Inc., Aurobindo Pharma Limited, Endo International plc., Hisamitsu Pharmaceutical Co., Inc., Intas Biopharmaceuticals, Johnson & Johnson, Medtronic plc, Mylan N.V., and Sanofi S.A.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Overactive Bladder Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Overactive Bladder Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Overactive Bladder Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Overactive Bladder Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Overactive Bladder Treatment Market?
6. What is the market share of the leading vendors in the Global Overactive Bladder Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Overactive Bladder Treatment Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allergan plc
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Endo International plc.
  • Intas Biopharmaceuticals
  • Johnson & Johnson
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Therapy Type Outlook
3.4. Disease Type Outlook
3.5. Geography Outlook
3.6. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growth in number of people with overactive bladder (OAB) symptoms
5.1.1.2. Increase in aging population
5.1.2. Restraints
5.1.2.1. Adverse effects and risk associated with overactive bladder treatment
5.1.3. Opportunities
5.1.3.1. Overactive bladder clinical research trials and pipeline
5.1.4. Challenges
5.1.4.1. Limited awareness of OAB condition
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Overactive Bladder Treatment Market, by Therapy Type
6.1. Introduction
6.2. Anticholinergic
6.3. BOTO
6.4. Darifenacin
6.5. Fesoterodine
6.6. Mirabegron
6.7. Neurostimulation
6.8. Oxybutynin
6.9. Solifenacin

7. Overactive Bladder Treatment Market, by Disease Type
7.1. Introduction
7.2. Idiopathic Bladder Overactivity
7.3. Neurogenic Bladder Overactivity

8. Americas Overactive Bladder Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Overactive Bladder Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Thailand

10. Europe, Middle East & Africa Overactive Bladder Treatment Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Allergan plc
12.2. Apotex Inc.
12.3. Aurobindo Pharma Limited
12.4. Endo International plc.
12.5. Hisamitsu Pharmaceutical Co., Inc.
12.6. Intas Biopharmaceuticals
12.7. Johnson & Johnson
12.8. Medtronic plc
12.9. Mylan N.V.
12.10. Sanofi S.A.

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2020 (USD MILLION)
FIGURE 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2020 (USD MILLION)
FIGURE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: MARKET DYNAMICS
FIGURE 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2020 VS 2026 (%)
FIGURE 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2020 VS 2026 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2026
FIGURE 11. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTO, 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTO, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DARIFENACIN, 2018-2026 (USD MILLION)
FIGURE 16. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DARIFENACIN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 17. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY FESOTERODINE, 2018-2026 (USD MILLION)
FIGURE 18. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY FESOTERODINE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 19. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY MIRABEGRON, 2018-2026 (USD MILLION)
FIGURE 20. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY MIRABEGRON, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 21. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2026 (USD MILLION)
FIGURE 22. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 23. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY OXYBUTYNIN, 2018-2026 (USD MILLION)
FIGURE 24. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY OXYBUTYNIN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 25. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SOLIFENACIN, 2018-2026 (USD MILLION)
FIGURE 26. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SOLIFENACIN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 27. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2020 VS 2026 (%)
FIGURE 28. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2020 VS 2026 (USD MILLION)
FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2026
FIGURE 30. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY IDIOPATHIC BLADDER OVERACTIVITY, 2018-2026 (USD MILLION)
FIGURE 31. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY IDIOPATHIC BLADDER OVERACTIVITY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 32. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROGENIC BLADDER OVERACTIVITY, 2018-2026 (USD MILLION)
FIGURE 33. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROGENIC BLADDER OVERACTIVITY, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 34. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 35. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 37. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 38. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 39. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 40. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 41. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 42. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 43. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 44. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 45. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 46. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 47. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 48. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 49. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 50. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 51. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 52. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 53. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 54. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 56. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 57. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 58. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 59. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 60. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 61. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 62. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 63. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 64. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 65. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 66. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 67. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 68. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 69. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: FPNV POSITIONING MATRIX
FIGURE 70. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 71. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY ANTICHOLINERGIC, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY BOTO, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DARIFENACIN, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY FESOTERODINE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY MIRABEGRON, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY OXYBUTYNIN, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY SOLIFENACIN, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 13. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 14. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY IDIOPATHIC BLADDER OVERACTIVITY, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 15. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY NEUROGENIC BLADDER OVERACTIVITY, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 16. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 17. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 18. AMERICAS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 19. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 20. ARGENTINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 21. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 22. BRAZIL OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 23. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 24. CANADA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 25. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 26. MEXICO OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 27. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 28. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 29. UNITED STATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 30. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 31. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 32. ASIA-PACIFIC OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 33. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 34. AUSTRALIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 35. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 36. CHINA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 37. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 38. INDIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 39. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 40. INDONESIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 41. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 42. JAPAN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 43. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 44. MALAYSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 45. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 46. PHILIPPINES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 47. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 48. SINGAPORE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 49. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 50. SOUTH KOREA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 51. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 52. THAILAND OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 56. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 57. FRANCE OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 58. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 59. GERMANY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 60. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 61. ITALY OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 62. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 63. NETHERLANDS OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 64. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 65. QATAR OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 66. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 67. RUSSIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 68. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 69. SAUDI ARABIA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 70. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 71. SOUTH AFRICA OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 72. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 73. SPAIN OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 74. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 75. UNITED ARAB EMIRATES OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 76. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2026 (USD MILLION)
TABLE 77. UNITED KINGDOM OVERACTIVE BLADDER TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD MILLION)
TABLE 78. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: SCORES
TABLE 79. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: BUSINESS STRATEGY
TABLE 80. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: PRODUCT SATISFACTION
TABLE 81. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: RANKING
TABLE 82. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 83. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: MERGER & ACQUISITION
TABLE 84. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 85. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 86. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: INVESTMENT & FUNDING
TABLE 87. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 88. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Allergan plc
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Endo International plc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Intas Biopharmaceuticals
  • Johnson & Johnson
  • Medtronic plc
  • Mylan N.V.
  • Sanofi S.A.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll